Home > Oncology > ASCO 2020 > Genitourinary Cancer > Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma

Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma

The randomised, phase 3 IMvigor010 study did not meet its primary endpoint of disease-free survival (DFS) after treatment with adjuvant atezolizumab in patients with muscle-invasive urothelial cancer. Overall survival (OS) follow-up is ongoing. Additional exploratory biomarkers and subgroup analyses may warrant further study.

Radical surgery with or without cisplatin-based neoadjuvant chemotherapy is the current standard-of-care for muscle-invasive urothelial carcinoma. However, there is no conclusive level I evidence for adjuvant chemotherapy value with regard to OS, and only up to 50% of patients are eligible for cisplatin-based chemotherapy. Atezolizumab, an anti-PD-L1 antibody, is indicated as monotherapy in multiple locally advanced or metastatic urothelial carcinoma disease settings.

The IMvigor010 study evaluated the benefit of adjuvant atezolizumab versus observation in patients with high-risk muscle-invasive urothelial carcinoma of the blad...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on